231 related articles for article (PubMed ID: 34495306)
41. Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma.
Kowata S; Seki Y; Tsukushi Y; Sato T; Asano K; Maeta T; Yashima-Abo A; Sasaki R; Okano Y; Oyake T; Ito S
Int J Hematol; 2023 Dec; 118(6):751-757. PubMed ID: 37488284
[TBL] [Abstract][Full Text] [Related]
42. Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.
Greve P; Beishuizen A; Hagleitner M; Loeffen J; Veening M; Boes M; Peperzak V; Diez C; Meyer-Wentrup F
Front Immunol; 2023; 14():1229558. PubMed ID: 37583696
[TBL] [Abstract][Full Text] [Related]
43. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
44. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
45. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.
McLaughlin LP; Rouce R; Gottschalk S; Torrano V; Carrum G; Wu MF; Hoq F; Grilley B; Marcogliese AM; Hanley PJ; Gee AP; Brenner MK; Rooney CM; Heslop HE; Bollard CM
Blood; 2018 Nov; 132(22):2351-2361. PubMed ID: 30262660
[TBL] [Abstract][Full Text] [Related]
46. Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.
Herrera AF; Palmer J; Adhikarla V; Yamauchi D; Poku EK; Bading J; Yazaki P; Dandapani S; Mei M; Chen R; Cao T; Karras N; McTague P; Nademanee A; Popplewell L; Sahebi F; Shively JE; Simpson J; Smith DL; Song J; Spielberger R; Tsai NC; Thomas SH; Forman SJ; Colcher D; Wu AM; Wong J; Smith E
Blood Adv; 2021 Dec; 5(23):5300-5311. PubMed ID: 34638132
[TBL] [Abstract][Full Text] [Related]
47. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
Cao Y; Lu W; Sun R; Jin X; Cheng L; He X; Wang L; Yuan T; Lyu C; Zhao M
Front Oncol; 2019; 9():767. PubMed ID: 31482064
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study.
Amraee A; Evazi MR; Shakeri M; Roozbeh N; Ghazanfarpour M; Ghorbani M; Ansari J; Darvish L
Clin Transl Oncol; 2019 Aug; 21(8):1093-1103. PubMed ID: 30739242
[TBL] [Abstract][Full Text] [Related]
49. Targeting Immune System Alterations in Hodgkin Lymphoma.
Grover NS; Savoldo B
Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
[TBL] [Abstract][Full Text] [Related]
50. Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Hematol Oncol; 2020 Dec; 38(5):737-741. PubMed ID: 32905626
[TBL] [Abstract][Full Text] [Related]
51. Performance of CT Compared with
Mokrane FZ; Chen A; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Duléry R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Houot R; Dercle L
Radiology; 2020 Jun; 295(3):651-661. PubMed ID: 32286191
[TBL] [Abstract][Full Text] [Related]
52. Early
Chen A; Mokrane FZ; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Dulery R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Armand P; Houot R; Dercle L
J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
[TBL] [Abstract][Full Text] [Related]
53. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ
J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081
[TBL] [Abstract][Full Text] [Related]
54. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH; Moskowitz AJ; Bartlett NL; Vose JM; Ramchandren R; Feldman TA; LaCasce AS; Christian BA; Ansell SM; Moskowitz CH; Brown L; Zhang C; Taft D; Ansari S; Sacchi M; Ho L; Herrera AF
Blood; 2021 Aug; 138(6):427-438. PubMed ID: 33827139
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Herbaux C; Gauthier J; Brice P; Drumez E; Ysebaert L; Doyen H; Fornecker L; Bouabdallah K; Manson G; Ghesquières H; Tabrizi R; Hermet E; Lazarovici J; Thiebaut-Bertrand A; Chauchet A; Demarquette H; Boyle E; Houot R; Yakoub-Agha I; Morschhauser F
Blood; 2017 May; 129(18):2471-2478. PubMed ID: 28270452
[TBL] [Abstract][Full Text] [Related]
56. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
Zhao L; Yang Y; Li W; Li T; Gao Q
Immunotherapy; 2018 Aug; 10(11):913-917. PubMed ID: 30149764
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.
Fedorova LV; Lepik KV; Volkov NP; Kotselyabina PV; Borzenkova ES; Popova MO; Beynarovich AV; Baykov VV; Kozlov AV; Moiseev IS; Mikhailova NB; Kulagin AD
Int J Clin Oncol; 2022 Mar; 27(3):626-632. PubMed ID: 34826011
[TBL] [Abstract][Full Text] [Related]
58. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.
Martínez C; Carpio C; Heras I; Ríos-Herranz E; Buch J; Gutierrez A; Romero S; Zeberio I; García-García I; Rodriguez-Izquierdo A; Alonso R; Bargay J; Barrenetxea C; Domingo-Doménech E; de Haro ME; Palomera L; García-Sanz R;
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1534-1542. PubMed ID: 32068094
[TBL] [Abstract][Full Text] [Related]
59. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
60. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Cruz CR; Gerdemann U; Leen AM; Shafer JA; Ku S; Tzou B; Horton TM; Sheehan A; Copeland A; Younes A; Rooney CM; Heslop HE; Bollard CM
Clin Cancer Res; 2011 Nov; 17(22):7058-66. PubMed ID: 21908573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]